Biological Approaches to Therapy of Pancreatic Cancer
Authors:
- Han Hsi WongHWHan Hsi Wong
- Nicholas R. LemoineNLNicholas R. Lemoine
- 1 October 2008
- journal article
- review article
- Published by Elsevier in Pancreatology
- Vol. 8 (4-5) , 431-461
Abstract
Pancreatic cancer is a lethal disease and notoriously difficult to treat. Only a small proportion is curative by surgical resection, whilst standard chemotherapy for patients with advanced disease has only modest effect with substantial toxicity. Clearly there is a need for the continual development of novel therapeutic agents to improve the current situation. Improvement of our understanding of the disease has generated a large number of studies on biological approaches targeting the molecular abnormalities of pancreatic cancer, including gene therapy and signal transduction inhibition, antiangiogenic and matrix metalloproteinase inhibition, oncolytic viral therapy and immunotherapy. This article provides a review of these approaches, both investigated in the laboratories and in subsequent clinical trials.Keywords
This publication has 369 references indexed in Scilit:
- Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinomaDiagnostic Cytopathology, 2007
- Retracted: In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancerInternational Journal of Cancer, 2006
- Unlocking the potential of the human genome with RNA interferenceNature, 2004
- Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancerInternational Journal of Cancer, 2004
- Pancreatic cancer growth is inhibited by blockade of VEGF-RIISurgery, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursEuropean Journal of Cancer, 2003
- The molecular genetics of pancreatic ductal carcinoma:: a reviewSurgical Oncology, 2000
- Suppression of Pancreatic Cancer by the Dominant NegativerasMutant, N116YJournal of Surgical Research, 1996
- Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.Journal of Clinical Investigation, 1992